Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase

Stefan Kubicek(Research Institute of Molecular Pathology), Roderick J. O’Sullivan(Research Institute of Molecular Pathology), Elias August(Boehringer Ingelheim (Germany)), Eugene R. Hickey(Boehringer Ingelheim (Germany)), Qiang Zhang(Boehringer Ingelheim (Germany)), Miguel L. Teodoro(Boehringer Ingelheim (Germany)), Stephen Rea(Research Institute of Molecular Pathology), Karl Mechtler(Research Institute of Molecular Pathology), Jennifer A. Kowalski(Boehringer Ingelheim (Germany)), Carol Homon(Boehringer Ingelheim (Germany)), Terence A. Kelly(Boehringer Ingelheim (Germany)), Thomas Jenuwein(Research Institute of Molecular Pathology)
Molecular Cell
February 1, 2007
10.1016/j.molcel.2007.01.017
Cited by 847

Abstract

Related Papers

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?
Stephen B. Baylin, Joyce E. Ohm|Nature reviews. Cancer|2006|1.6k
Epigenetic therapy of cancer: past, present and future
Christine B. Yoo, Peter A. Jones|Nature Reviews Drug Discovery|2006|1.3k
A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G <sub>0</sub> Cells
Hidesato Ogawa, Kei‐ichiro Ishiguro, Stefan Gaubatz et al.|Science|2002|766
The profile of repeat‐associated histone lysine methylation states in the mouse epigenome
Joost H.A. Martens, Roderick J. O’Sullivan, Ulrich Braunschweig et al.|The EMBO Journal|2005|662
G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis
Nirit Feldman, Ariela Gerson, Jia Fang et al.|Nature Cell Biology|2006|640